Larry K. Kociolek, MD, MSCI, and Stanford T. Shulman, MD

All articles by Larry K. Kociolek, MD, MSCI, and Stanford T. Shulman, MD

Biotherapeutics for the Prevention of Clostridium difficile Infection

August 16, 2017

Experts review biotherapeutics for the prevention of C difficile infection, including probiotics, fecal microbiota transplantation, and nontoxigenic C difficile.

Clostridioides Difficile

C difficile Treatment and Prevention: Novel Antibiotics and Immunologic Therapies

Larry K. Kociolek, MD, MSCI, and Stanford T. Shulman, MD

June 8, 2017

Experts review novel antibiotic therapies that may limit the impact on the gut microbiome, as well as passive immunization products that may bolster the immune response to C difficile toxins and possibly reduce the frequency of toxigenic strains.

Clostridioides Difficile

Review of Clostridium difficile Vaccines in Development

Larry K. Kociolek, MD, MSCI, and Stanford T. Shulman, MD

March 24, 2017

Drs Kociolek and Shulman, from the division of infectious diseases at the Ann & Robert H. Lurie Children’s Hospital of Chicago in Illinois, review all the current vaccine candidates in development for Clostridium difficile infection.

Next post in Clostridioides Difficile

Larry K. Kociolek, MD, MSCI, and Stanford T. Shulman, MD

All articles by Larry K. Kociolek, MD, MSCI, and Stanford T. Shulman, MD

Biotherapeutics for the Prevention of Clostridium difficile Infection

C difficile Treatment and Prevention: Novel Antibiotics and Immunologic Therapies

Review of Clostridium difficile Vaccines in Development

Probiotic Use Ineffective for Primary Prevention of Clostridioides difficile Infection in Select Hospitalized Patients